| Sign In to gain access to subscriptions and/or personal tools. |
Body-Fat Abnormalities in Patients With HIV: Progress and ChallengesInternal Medicine, Infectious Diseases Section, VA North Texas Healthcare System, UT Southwestern Medical School, Dallas, Texas, roger.bedimo{at}va.gov and/or roger.bedimo{at}utsouthwestern.edu The introduction of newer antiretroviral drugs has provided greater levels of HIV suppression with fewer of the metabolic effects, lipoatrophy, and body habitus changes associated with earlier therapies. Previously classified under the collective term, lipodystrophy, lipoatrophy and body-fat changes are now known to occur independently in some HIV-infected patients, depending on the type and duration of antiretroviral therapy and a myriad of factors including HIV infection alone that contribute significantly to these changes. This article reviews the current scientific literature and recent clinical trial results that distinguish lipoatrophy or dyslipidemia pathophysiologically from body-fat changes seen as central and peripheral lipohypertrophy and fat redistribution, as well as the nature and extent of changes associated with HIV infection alone and newer antiretroviral therapies. This information may assist physicians in identifying individual risk factors and choosing the type of antiretroviral therapy that may minimize these changes without loss of virologic suppression.
Key Words: body fat • lipoatrophy • antiretroviral therapy • HIV infection
This version was published on December
1, 2008 Journal of the International Association of Physicians in AIDS Care (JIAPAC), Vol. 7, No. 6,
292-305 (2008) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
